HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Jenburkt Pharmaceuticals Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 15 filings·Updated 7 Aug 2026
Showing 10 of 15 filings.
7 Aug 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.

Filed 11:41View Source
6 Aug 20261 filing
ResultFinancial Results

Jenburkt Pharmaceuticals Q1 FY2027 standalone results: revenue ₹3,551.20 lakhs, PAT ₹588.56 lakhs

Financial highlights

  • Revenue from operations ₹3,551.20 lakhs in Q1 FY2027, -0.04% YoY.
  • Total income ₹3,702.52 lakhs; YoY -1.35% to ₹3,758.39.
  • Total expenses ₹3,025.61 lakhs; QoQ down 3.60%.
  • PBT before tax ₹676.91 lakhs; QoQ down from ₹1,370.82.
  • Tax expense ₹88.35 lakhs; current ₹100.00, deferred -₹11.65.
  • Profit after tax ₹588.56 lakhs; YoY -24.5%.
  • EPS ₹13.34; Basic and Diluted for Q1 FY2027.
  • Total comprehensive income ₹738.81 lakhs.
  • Labour Codes impact ₹0 in Q1 FY2027; ₹395.11 lakhs in prior quarter.
  • Pharma segment only; no segment-wise reporting.
  • Limited review by DR Mehta & Associates; not an audit.
Filed 20:05View Source
13 Jul 20261 filing
Company UpdateChange in Registered Office Address

Jenburkt Pharmaceuticals shifts registered office within Mumbai, effective 21 July 2026

Registered office change

  • From: Nirmala Apartments, 93 Jay Prakash Road, Andheri West, Mumbai 400 058.
  • To: 14th Floor, Unicorn, Dattaji Salvi Marg, off Veera Desai Road, Andheri West, Mumbai 400 053.
  • Effective from 21 July 2026.
  • Within Mumbai city; ROC unchanged.
  • Board approval via circular resolution dated 13 July 2026.
  • Telephone, email and website unchanged.
Filed 18:43View Source
10 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Jenburkt confirms dematerialisation processed through 30 June 2026; securities listed and records updated

Dematerialisation processing and listing

  • Dematerialisation requests up to 30 June 2026 were processed and listed on exchanges.
  • Physical certificates dematerialised were mutilated and cancelled; depository name updated within 15 days.
Filed 15:53View Source
14 Apr 20261 filing
Company UpdateGeneral

Pursuant to SEBI Circular dated 10th August, 2021, we hereby confirm that, for the financial year ended 31st March, 2026, Jenburkt pharmaceuticals Limited is "not a large corporate" as ....

Filed 13:18View Source
7 Apr 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31-03-2026.

Filed 12:11View Source
23 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

Intimation of closure of trading window of Jenburkt Phamaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations, 2015.

Filed 13:11View Source
4 Feb 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication for Unaudited statndalone financial Statement for the quarter and nine months ended on 31st Decemeber, 2025.

Filed 12:38View Source
28 Jan 20261 filing
Board Meeting

Jenburkt Pharmaceuticals Ltd - 524731 - Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter And Nine Months Ended On 31St December, 2025.

🗓️ Meeting Details

  • Board meeting scheduled for 3 February 2026 at the company's registered office.

📊 Financial Performance

  • To take on record standalone unaudited financial results for quarter and nine months ended 31 December 2025.
Filed 11:34View Source
7 Jan 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations, 2018, for the quarter ended on 31.12.2025.

Filed 15:06View Source
Showing 10 of 15 filings